7/24 TE-RegenMed-StemCell feed

TE-RegenMed-StemCell feed CIRM Defends Legality of Barring Public From Marriott Meeting July 23, 2010 at 2:31 PM The California stem cell agency says it did not violate state open meeting laws when it barred two members of the public from a meeting in June at a San Francisco hotel. In an unsolicited note earlier this month to the California Stem Cell Report, Ian Sweedler, deputy legal counsel for CIRM, said, "The Bagley-Keene Open Meeting Act applies to multimember boards or commissions, like the ICOC (   Collagen-matrix allograft augmentation of bilateral rupture of the achilles tendon. July 23, 2010 at 9:09 AM Related Articles Collagen-matrix allograft augmentation of bilateral rupture of the achilles tendon. Foot Ankle Int. 2010 Jun;31(6):556-9 Authors: Kearney RS, Costa ML PMID: 20557825 [PubMed - indexed for MEDLINE]   A review of bioactive materials and chronic wounds. July 23, 2010 at 9:09 AM Related Articles A review of bioactive materials and chronic wounds. Cutis. 2010 May;85(5):259-66 Authors: Plotner AN, Mostow EN An increasing number of bioactive materials are indicated for the treatment of chronic lower extremity ulcers. They are promising adjuncts to standard therapy. When used in conjunction with standard therapy for venous leg ulcers and diabetic foot ulcers, bioactive materials may increase the likelihood and rate of healing. This review compares commonly available bioactive materials indicated for chronic wound healing and provides an overview of the relevant Current Procedural Terminology (CPT) and Healthcare Common Procedure Coding System (HCPCS) codes for these products. PMID: 20540417 [PubMed - indexed for MEDLINE]   Efficacy and safety of biologicals against immune-mediated diseases: do benefits outweigh risks? July 23, 2010 at 9:09 AM Related Articles Efficacy and safety of biologicals against immune-mediated diseases: do benefits outweigh risks? Drugs Today (Barc). 2010 Feb;46(2):119-36 Authors: Korkina L, Trakhtman P, De Luca C, Leoni L, Raskovic D, Pastore S The success of molecular biology in identifying molecular pathways underlying chronic immune-mediated diseases and the rapid development of gene/cell engineering biotechnologies has resulted in the development of a number of targeted biological drugs, which have revolutionized the therapy of these diseases. Numerous data published over the last 10-15 years demonstrate a dramatic improvement in the clinical efficacy of biologics compared with conventional drugs. However, professional and public concern about serious biological drug-associated adverse events has also been growing steadily. We critically analyze recent literature on the efficacy and safety of biologics in the management of rheumatoid arthritis, psoriasis, psoriatic arthritis and immune thrombocytopenia. Our analysis of benefits, resistance to the therapy, risk of infections, tumors and other serious complications related to chronic administration of biologics is based on the molecular/cellular mechanisms of their interaction with the immune system. We also address whether it is feasible to attenuate the risks associated with biologics without limiting their benefits. PMID: 20393640 [PubMed - indexed for MEDLINE]   Stem cell engineering for cardiac tissue regeneration. July 23, 2010 at 9:09 AM Related Articles Stem cell engineering for cardiac tissue regeneration. Cardiology. 2010;115(3):191-3 Authors: Yoshida M, Oh H PMID: 20145395 [PubMed - indexed for MEDLINE]   Thunder Road--the beginning of a new era. July 23, 2010 at 6:34 AM Related Articles Thunder Road--the beginning of a new era. Int J Artif Organs. 2010 Jan;33(1):3-4 Authors: Catapano G, Kein JB PMID: 20162527 [PubMed - indexed for MEDLINE]   This email was sent to regenmd@gmail.com.  Account Login Don't want to receive this feed any longer? Unsubscribe here This email was carefully delivered by Feed My Inbox. 230 Franklin Road Suite 814 Franklin, TN 37064